Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

One of The World's Most Used Drugs May Lower Dementia Risk – But There's a Catch : ScienceAlert (opens in a new tab)

sciencealert.com · 2026-10-01

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 3 supported
  • 2 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Three of five claims match the study. This overall rating is based only on the claims we could check. Two claims the study doesn't address.

  • 3 supported
  • 2 not covered
Open claim evidence
3
Source paper

Source layer

The 2 papers the story cites

Source study separated from background citations.

The research anchor for the report.

Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredThe study used data from more than 13,500 older adults in Australia and the US and was published in Alzheimer's & Dementia.View evidenceHide evidence

As statedmore than 13,500 participants

Why this verdict

The abstract-level profile supports the participant count: ASPREE included n=13,541, which is more than 13,500. However, the supplied paper profile does not verify the Australia/US setting or the publication venue, Alzheimer's & Dementia, so the full claim is not verifiable at this evidence depth.

1

Study evidence

Among participants in the highest quintile of platelet-count PGS003548, randomized aspirin allocation was associated with substantially lower incident dementia risk versus placebo.HR 0.28 (95% CI 0.15 to 0.52)

“In the ASPirin in Reducing Events in the Elderly (ASPREE) trial (n = 13,541), we screened 5182 polygenic risk scores (PGSs) for aspirin interactions on dementia and major bleeding.”
2

Study evidence

In the highest quintile of a platelet-count polygenic score (PGS003548), aspirin allocation was associated with an increased risk of major bleeding compared with placebo.HR 2.13 (95% CI 1.36 to 3.34)

“we screened 5182 polygenic risk scores (PGSs) for aspirin interactions on dementia and major bleeding.”
Claim 2 of 5Not coveredThe lead author cautioned that people should not start aspirin for dementia prevention without consulting a doctor and said the finding needs confirmation in other studies and a trial designed specifically for people with this genetic profile.View evidenceHide evidence

Why this verdict

The paper profile supports the substance that the findings are hypothesis-generating, require independent validation, and involve an important bleeding trade-off. However, the lead-author quote, advice to consult a doctor before starting aspirin for dementia prevention, and the specific statement about a trial designed for this genetic profile are not directly verifiable from the supplied abstract-level profile.

1

Study evidence

Among participants in the highest quintile of platelet-count PGS003548, randomized aspirin allocation was associated with substantially lower incident dementia risk versus placebo.HR 0.28 (95% CI 0.15 to 0.52)

“In the ASPirin in Reducing Events in the Elderly (ASPREE) trial (n = 13,541), we screened 5182 polygenic risk scores (PGSs) for aspirin interactions on dementia and major bleeding.”
2

Study evidence

In the highest quintile of a platelet-count polygenic score (PGS003548), aspirin allocation was associated with an increased risk of major bleeding compared with placebo.HR 2.13 (95% CI 1.36 to 3.34)

“we screened 5182 polygenic risk scores (PGSs) for aspirin interactions on dementia and major bleeding.”
Claim 3 of 5SupportedAn analysis of a large randomized controlled trial found that taking daily aspirin was associated with a lower relative risk of dementia among people with certain genes.View evidenceHide evidence

Why this verdict

The paper profile supports a secondary analysis of the ASPREE randomized aspirin trial testing aspirin-by-polygenic-score interactions for incident dementia. It reports that aspirin allocation was associated with lower incident dementia risk in a high platelet-count polygenic-score subgroup. The story frames this as an association and is appropriately hedged.

1

Study evidence

Among participants in the highest quintile of platelet-count PGS003548, randomized aspirin allocation was associated with substantially lower incident dementia risk versus placebo.HR 0.28 (95% CI 0.15 to 0.52)

“In the ASPirin in Reducing Events in the Elderly (ASPREE) trial (n = 13,541), we screened 5182 polygenic risk scores (PGSs) for aspirin interactions on dementia and major bleeding.”
2

Study evidence

Platelet-related PGSs were over-represented among nominally significant aspirin×PGS interactions.enrichment_OR = 54.7, p = 3.1 × 10^-18

“Platelet-related PGS accounted for 18/112 nominally significant interactions (enrichment_OR = 54.7, p = 3.1 × 10-18).”
Claim 4 of 5SupportedAmong participants with genetic scores associated with higher platelet counts, those taking aspirin were reported to have a 70 percent lower risk of developing dementia over the trial than those taking placebo.View evidenceHide evidence

As stated70 percent lower relative risk

Why this verdict

The paper profile reports that in the highest quintile of platelet-count PGS003548, aspirin allocation was associated with reduced incident dementia versus placebo, HR 0.28 with 95% CI 0.15–0.52. Describing this as about a 70% lower relative risk is a reasonable approximation of the hazard-ratio result, and the story frames it associationally.

1

Study evidence

Among participants in the highest quintile of platelet-count PGS003548, randomized aspirin allocation was associated with substantially lower incident dementia risk versus placebo.HR 0.28 (95% CI 0.15 to 0.52)

“In the ASPirin in Reducing Events in the Elderly (ASPREE) trial (n = 13,541), we screened 5182 polygenic risk scores (PGSs) for aspirin interactions on dementia and major bleeding.”
2

Study evidence

Platelet-related PGSs were over-represented among nominally significant aspirin×PGS interactions.enrichment_OR = 54.7, p = 3.1 × 10^-18

“Platelet-related PGS accounted for 18/112 nominally significant interactions (enrichment_OR = 54.7, p = 3.1 × 10-18).”
Claim 5 of 5SupportedSerious bleeds were roughly twice as common among those taking aspirin.View evidenceHide evidence

As statedroughly twice as common

Why this verdict

The paper profile reports increased major bleeding in the same high platelet-count PGS subgroup, HR 2.13 with 95% CI 1.36–3.34, which is consistent with 'roughly twice' the risk. The claim would be clearer if it explicitly stated that this estimate is for the high-PGS subgroup and is a hazard ratio, but it does not materially outrun the abstract-level evidence.

1

Study evidence

In the highest quintile of a platelet-count polygenic score (PGS003548), aspirin allocation was associated with an increased risk of major bleeding compared with placebo.HR 2.13 (95% CI 1.36 to 3.34)

“we screened 5182 polygenic risk scores (PGSs) for aspirin interactions on dementia and major bleeding.”
2

Study evidence

Platelet-related PGSs were over-represented among nominally significant aspirin×PGS interactions.enrichment_OR = 54.7, p = 3.1 × 10^-18

“Platelet-related PGS accounted for 18/112 nominally significant interactions (enrichment_OR = 54.7, p = 3.1 × 10-18).”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The analysis involved a broad genome-wide/polygenic-score interaction screen with many tested PGSs, post-screen subgroup analyses, and multiple-testing considerations.

    The paper profile emphasizes screening thousands of PGSs, analyzing 1,848 after QC, applying Bonferroni correction, and then examining subgroups by PGS quantiles. The story caveats mention replication and trial design but do not clearly convey the multiplicity/post-screening context, which is important for interpreting the subgroup signal.

    From Secondary analysis of randomized trial (aspirin vs placebo) with genome-wide PGS interaction screen; Post-screen enrichm

  • Three significant platelet-count PGSs were highly correlated, suggesting the findings may represent a single underlying genetic signal rather than multiple independent modifiers.

    This limitation appears in the abstract-level paper profile but is not reflected in the story's listed caveats.

    From Secondary analysis of randomized trial (aspirin vs placebo) with genome-wide PGS interaction screen; Post-screen enrichm

4 things the story did carry across
  • The study is a secondary analysis of the randomized ASPREE aspirin-versus-placebo trial, not a new trial designed specifically for this genetic subgroup.
  • The main dementia signal concerns a high platelet-count polygenic-score subgroup, especially the highest quintile of PGS003548, with aspirin associated with lower incident dementia risk, HR 0.28.
  • The same high platelet-count PGS subgroup also had increased major bleeding with aspirin, HR 2.13, making benefit-harm balance unresolved.
  • The findings are hypothesis-generating and require independent validation before clinical application.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

3

Evidence read

study summary

Lead result

secondary data

1Lead resultsecondary dataIdentify whether any polygenic scores (PGSs) modify the effect of randomized aspirin allocation on incident dementia risk in the ASPREE trial (gene×treatment interaction screen).Secondary analysis of randomized trial (aspirin vs placebo) with genome-wide PGS interaction screenExpand

In plain English

Secondary analysis of the ASPREE randomized trial screened 1,848 QC'd polygenic scores (from an initial 5,182) for interaction with randomized aspirin allocation on incident dementia using Cox models adjusted for age, sex, APOE status, and ancestry. Platelet-count related PGSs were enriched among nominal interactions; three highly correlated platelet-count PGSs passed Bonferroni correction. In participants in the highest quintile of platelet-count PGS003548, aspirin allocation was associated with lower incident dementia (HR 0.28, 95% CI 0.15–0.52) and higher major bleeding (HR 2.13, 95% CI 1.36–3.34). Authors frame findings as hypothesis-generating and requiring validation.

Key findings

  • Among participants in the highest quintile of platelet-count PGS003548, randomized aspirin allocation was associated with substantially lower incident dementia risk versus placebo.HR 0.28 (95% CI 0.15 to 0.52)
  • In the same high platelet-count PGS subgroup, randomized aspirin allocation was associated with increased major bleeding.HR 2.13 (95% CI 1.36 to 3.34)
“In the ASPirin in Reducing Events in the Elderly (ASPREE) trial (n = 13,541), we screened 5182 polygenic risk scores (PGSs) for aspirin interactions on dementia and major bleeding.”
What this piece can’t prove
  • Reported results are from a secondary, hypothesis-generating genome-wide interaction screen and require independent validation.
  • Three significant PGSs are highly correlated, which may reflect a single underlying genetic signal rather than multiple independent modifiers.
  • Abstract does not report subgroup event counts, full model diagnostics, proportional hazards assumption checks, or replication analyses.
  • Potential clinical trade-off: reduced dementia risk in the high-PGS subgroup accompanied by increased major bleeding; net benefit/harm not established.
2secondary dataAssess whether PGS-defined subgroups that appear to benefit (or be harmed) for dementia also show modified risk of major bleeding with aspirin allocation (safety interaction).Secondary analysis of randomized trial dataExpand

In plain English

Secondary analysis of the ASPREE randomized trial examined whether platelet-count polygenic scores (PGSs) modify aspirin's safety effect on major bleeding. In the highest quintile of a platelet-count PGS (PGS003548) aspirin allocation was associated with increased major bleeding (HR 2.13, 95% CI 1.36–3.34). These subgroup safety findings are reported alongside a dementia benefit in the same PGS subgroup and are described as hypothesis-generating and requiring validation.

Key findings

  • In the highest quintile of a platelet-count polygenic score (PGS003548), aspirin allocation was associated with an increased risk of major bleeding compared with placebo.HR 2.13 (95% CI 1.36 to 3.34)
“we screened 5182 polygenic risk scores (PGSs) for aspirin interactions on dementia and major bleeding.”
What this piece can’t prove
  • Authors characterize findings as hypothesis-generating and state they require independent validation.

1 further detail could not be confirmed from the summary.

3secondary dataCharacterize and contextualize significant interactions (e.g., platelet-count PGS enrichment; subgroup estimates by quintiles/tertiles/deciles/top 5%) to support interpretation as hypothesis-generating precision-medicine signals.Post-screen enrichment and subgroup interaction analysis in RCT (secondary analysis of ASPREE)Expand

In plain English

Post-screening analyses of PGS-by-aspirin interactions in the ASPREE randomized trial found a marked enrichment of nominal interactions among platelet-related polygenic scores and identified three correlated platelet-count PGSs that survived multiple testing. In the highest quintile of the platelet-count PGS003548, randomized allocation to aspirin was associated with substantially lower incident dementia risk (HR 0.28, 95% CI 0.15–0.52) but higher major bleeding risk (HR 2.13, 95% CI 1.36–3.34). Similar interaction patterns were reported using alternative high-risk cut-points (top tertile, decile, top 5%). The authors frame these as hypothesis-generating signals requiring validation.

Key findings

  • Platelet-related PGSs were over-represented among nominally significant aspirin×PGS interactions.enrichment_OR = 54.7, p = 3.1 × 10^-18
  • Three highly correlated platelet-count PGSs passed multiple testing correction in the interaction screen.
“Platelet-related PGS accounted for 18/112 nominally significant interactions (enrichment_OR = 54.7, p = 3.1 × 10-18).”
What this piece can’t prove
  • Analyses are post-screening/subgroup characterizations and presented as hypothesis-generating; independent validation is required.
  • Enrichment and subgroup findings arise from secondary analyses of trial data after screening many PGSs; despite Bonferroni correction for interactions, post-selection inference and multiplicity remain concerns.

1 further detail could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 16 candidate papers

And 10 more candidates considered.